PCM
Penserra Capital Management Portfolio holdings
AUM
$7.17B
1-Year Return
49.58%
This Quarter Return
+7.37%
1 Year Return
+49.58%
3 Year Return
+118.16%
5 Year Return
+229.83%
10 Year Return
–
AUM
$4.82B
AUM Growth
+$264M
(+5.8%)
Cap. Flow
+$258M
Cap. Flow
% of AUM
5.34%
Top 10 Holdings %
Top 10 Hldgs %
29.81%
Holding
1,229
New
73
Increased
407
Reduced
448
Closed
96
Top Buys
| 1 |
United Parcel Service
UPS
|
+$92.8M |
| 2 |
Marathon Petroleum
MPC
|
+$90.6M |
| 3 |
Nucor
NUE
|
+$49.2M |
| 4 |
Apple
AAPL
|
+$41.4M |
| 5 |
Schlumberger
SLB
|
+$33.4M |
Top Sells
| 1 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$77.8M |
| 2 |
Amgen
AMGN
|
+$64M |
| 3 |
Devon Energy
DVN
|
+$52.3M |
| 4 |
Merck
MRK
|
+$49M |
| 5 |
Aflac
AFL
|
+$44.7M |
Sector Composition
| 1 | Technology | 22.93% |
| 2 | Consumer Discretionary | 13.4% |
| 3 | Financials | 10.7% |
| 4 | Healthcare | 8.47% |
| 5 | Industrials | 7.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
776
Expeditors International
EXPD
$16.5B
| $95K | ﹤0.01% |
872
| – | – |
|
777
Raymond James Financial
RJF
$33.1B
| $95K | ﹤0.01% |
1,026
| – | – |
|
778
Fifth Third Bancorp
FITB
$30.1B
| $94K | ﹤0.01% |
3,566
-2
| -0.1% | -$53 |
|
|
ZYNE
779
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $94K | ﹤0.01% |
219,146
+3,424
| +2% | +$1.47K |
|
780
Editas Medicine
EDIT
$251M
| $92K | ﹤0.01% |
12,720
+430
| +3% | +$3.11K |
|
781
Wabtec
WAB
$32.6B
| $91K | ﹤0.01% |
904
| – | – |
|
782
IDEX
IEX
$12.4B
| $90K | ﹤0.01% |
397
-13,445
| -97% | -$3.05M |
|
783
Allogene Therapeutics
ALLO
$253M
| $89K | ﹤0.01% |
18,110
+4,890
| +37% | +$24K |
|
784
Cincinnati Financial
CINF
$24B
| $89K | ﹤0.01% |
805
| – | – |
|
785
Regions Financial
RF
$24.1B
| $89K | ﹤0.01% |
4,865
| – | – |
|
|
TTM
786
DELISTED
Tata Motors Limited
TTM
| $89K | ﹤0.01% |
3,503
-538
| -13% | -$13.7K |
|
787
Broadridge
BR
$29.7B
| $88K | ﹤0.01% |
608
-2
| -0.3% | -$289 |
|
|
TSVT
788
DELISTED
2seventy bio
TSVT
| $87K | ﹤0.01% |
8,530
+210
| +3% | +$2.14K |
|
|
VERV
789
DELISTED
Verve Therapeutics
VERV
| $87K | ﹤0.01% |
6,050
+440
| +8% | +$6.33K |
|
790
Bristol-Myers Squibb
BMY
$95.1B
| $86K | ﹤0.01% |
1,255
-44,757
| -97% | -$3.07M |
|
791
Las Vegas Sands
LVS
$36.9B
| $86K | ﹤0.01% |
1,512
| – | – |
|
792
Prime Medicine
PRME
$693M
| $86K | ﹤0.01% |
7,000
-570
| -8% | -$7K |
|
793
Markel Group
MKL
$24.4B
| $84K | ﹤0.01% |
66
| – | – |
|
794
Enterprise Products Partners
EPD
$68.1B
| $83K | ﹤0.01% |
3,245
+991
| +44% | +$25.3K |
|
795
Zoom
ZM
$25.5B
| $83K | ﹤0.01% |
1,139
| – | – |
|
796
Corpay
CPAY
$22B
| $82K | ﹤0.01% |
389
| – | – |
|
797
Arqit Quantum
ARQQ
$405M
| $81K | ﹤0.01% |
2,323
+150
| +7% | +$5.23K |
|
798
Molina Healthcare
MOH
$9.51B
| $81K | ﹤0.01% |
305
| – | – |
|
799
Norfolk Southern
NSC
$61.8B
| $81K | ﹤0.01% |
388
+376
| +3,133% | +$78.5K |
|
800
VICI Properties
VICI
$35.5B
| $81K | ﹤0.01% |
2,534
-766
| -23% | -$24.5K |
|